Shire Completes Acquisition of Advanced BioHealing, Inc.

DUBLIN, June 28, 2011 -

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that following the
satisfaction of the closing conditions, including the expiry of the
waiting period under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, the acquisition of Advanced BioHealing, Inc. (”ABH”),
as first announced on May 17, 2011, has been completed.

The Advanced BioHealing business becomes part of Shire’s
Specialty Pharmaceuticals business, led by Mike Cola, and will
leverage biologic manufacturing expertise from Shire’s Human
Genetic Therapies business. Kevin Rakin, Chief Executive Officer of
Advanced BioHealing, will continue to lead this business within the
Shire organization.

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the
specialist physician.  Shire focuses its business on attention
deficit hyperactivity disorder (ADHD), human genetic therapies
(HGT) and gastrointestinal (GI) diseases as well as opportunities
in other therapeutic areas to the extent they arise through
acquisitions.  Shire’s in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights.  Shire
believes that a carefully selected and balanced portfolio of
products with strategically aligned and relatively small-scale
sales forces will deliver strong results.

For further information on Shire, please visit the Company’s
website: href="www.shire.com/">www.shire.com.

“SAFEHARBOR” STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve
a number of risks and uncertainties and are subject to change at
any time. In the event such risks or uncertainties materialize, the
Company’s results could be materially adversely affected. The risks
and uncertainties include, but are not limited to, risks associated
with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company’s
Specialty Pharmaceuticals and Human Genetic Therapies products, as
well as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the
Company’s products; the Company’s ability to manufacture its
products in sufficient quantities to meet demand; the impact of
competitive therapies on the Company’s products; the Company’s
ability to register, maintain and enforce patents and other
intellectual property rights relating to its products; the
Company’s ability to obtain and maintain government and other
third-party reimbursement for its products; and other risks and
uncertainties detailed from time to time in the Company’s filings
with the Securities and Exchange Commission.

For further information please
contact:

    Investor
    Relations        Eric Rojas (erojas@shire.com)         +1-781-482-0999
                     Sarah Elton-Farr
                     (seltonfarr@shire.com)                +44(0)1256-894157

    Media            Jessica Mann (jmann@shire.com)        +44(0)1256-894-280
                     Matthew Cabrey (mcabrey@shire.com)    +1-484-595-8248

.